Phase 1 · NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- ClinicalTrials.gov ID
- NCT06039826
- Indication
- Overweight
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 46
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Ethinyl Estradiol; Drug: Drospirenone
- Comparator
- Not reported
- Eligible ages
- 40 Years – 60 Years
- Locations
- 2 sites · United States
- Study start
- 12 Sept 2023
- Primary completion
- 11 Jul 2024
- Study completion
- 11 Jul 2024
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 26 Jul 2024
Endpoints
Primary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol; PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol; PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol; PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone; PK: Maximum Observed Concentration (Cmax) of Drospirenone; PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone